In recent years, the results of many studies have shown that RON, a member of the receptor tyrosine kinase protein family, has different alternative spliceosomes that account for the occurrence, development and chemotherapeutic drug resistance of GC and are expected to become a potential drug development target [31, 39, 56–58]. This evidence concerns the gene MST1R and gastric cancer.